CLPT ClearPoint Neuro, Inc.

CIK 0001285550 24 ready 8-Ks latest May 13, 2026, 4:05 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 24

Latest filing May 21, 2026, 4:30 PM ET

Top materiality 0.80

Event mix earnings ×11 · other_material ×6 · m_and_a ×3

Sentiment 15 pos · 2 neg · 7 neu

Latest earnings ▼ miss 2026-Q1

Recent 8-K filings for CLPT

Highest-materiality recent filing

ClearPoint Neuro secures up to $110M from Oberland Capital with $33.5M funded at closing

May 12, 2025, 7:59 PM ET debt materiality 0.80 positive item 1.01 item 8.01 item 9.01

Enters note agreement for up to $105M; $30M funded at closing, up to $25M optional second tranche, up to $50M third tranche.
Issues 275,808 shares at $12.69 in registered direct offering for $3.5M gross proceeds.

Read filing →

May 13, 2026, 4:05 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q1 revenue $12.1M (+43% YoY); guides FY2026 $52-56M

Record Q1 revenue of $12.1M; organic device growth 25% YoY; gross margin expanded to 64% from 60%.
March 17, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro reports Q4 revenue $10.4M (+34% YoY); FY 2025 revenue $37.0M (+18%); guides FY 2026 $52-56M

Q4 2025 revenue $10.4M including $1.2M from recent IRRAS acquisition; organic growth 19% YoY.
January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

ClearPoint Neuro Q4 2025 prelim revenue $10.4M (+20% YoY); FY2026 guidance $54-60M

Q4 2025 preliminary unaudited revenue ~$10.4M, 20% comparable sales growth over Q4 2024, excluding recent IRRA flow acquisition.
November 20, 2025, 6:59 PM ET M&A materiality 0.70 positive item 1.01 item 2.01 item 3.02 item 7.01 item 9.01 ◈ M&A Transactions

ClearPoint Neuro completes acquisition of IRRAS for $5M cash + 1.325M shares

Acquisition closed Nov 20, 2025; IRRAS shareholders received $5M cash and 1.325M CLPT shares.
November 6, 2025, 6:59 PM ET M&A materiality 0.70 positive item 1.01 item 7.01 item 9.01

ClearPoint Neuro to acquire IRRAS for $5M cash + 1.325M shares; combined 2026 rev $54-60M

Total consideration: $5M cash plus 1.325M ClearPoint shares; earnout of 25% of net IRRA flow sales above thresholds.
November 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q3 rev $8.9M (+9% YoY); narrows FY25 guide $36-38M; acquires IRRAS

Q3 revenue $8.9M, up 9% YoY; cash $38.2M as of Sept 30, 2025.
August 12, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q2 revenue record $9.2M (+17% YoY); secures up to $105M note financing

Record Q2 revenue $9.2M, up 17% YoY; neurosurgery segment revenue up 33% to $3.4M.
May 13, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro reports record Q1 revenue $8.5M, consumables up 104% YoY

Q1 revenue $8.5M (record), up 11% YoY; consumable product revenue grew 104% to $5.5M.
May 12, 2025, 7:59 PM ET debt materiality 0.80 positive item 1.01 item 8.01 item 9.01

ClearPoint Neuro secures up to $110M from Oberland Capital with $33.5M funded at closing

Enters note agreement for up to $105M; $30M funded at closing, up to $25M optional second tranche, up to $50M third tranche.
February 26, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro reports record FY2024 revenue $31.4M, 31% growth; guides FY2025 $36-41M

FY 2024 revenue $31.4M (+31% YoY); Q4 revenue $7.8M (+14% YoY).
November 7, 2024, 6:59 PM ET other material materiality 0.65 negative item 1.01 item 9.01

ClearPoint Neuro enters $50M ATM equity offering with Stifel

ATM agreement with Stifel allows sale of up to $50M in common stock from time to time.
November 7, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q3 revenue $8.1M (+41% YoY); FY guidance reaffirmed

Record quarterly revenue of $8.1M, up 41% YoY; navigation & device revenue $2.9M (+49%).
August 7, 2024, 7:59 PM ET earnings materiality 0.78 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q2 revenue $7.9M (+32% YoY); raises FY2024 guidance to $30-33M

Record quarterly revenue of $7.9M, up 32% YoY; product revenue more than doubled to $4.9M.
May 7, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

ClearPoint Neuro Q1 revenue $7.6M (+41% YoY); biologics revenue $4.3M (+61%); cash burn down 32%

Record quarterly revenue of $7.6M, up 41% YoY; biologics/drug delivery revenue up 61% to $4.3M.
March 12, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

ClearPoint Neuro Q4 revenue $6.8M (+32% YoY); FY2023 revenue $24M (+17%); reaffirms 2024 guidance $28M-$32M

Q4 2023 revenue $6.8M, up 32% YoY; full-year revenue $24.0M, up 17% YoY.
March 1, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 9.01

ClearPoint Neuro prices $15M public offering of 2.3M shares at $6.50

Offering of 2,307,694 shares of common stock at $6.50 per share; underwriters have 30-day option for 346,154 additional shares.

Earnings & guidance

2026-Q1 EPS reported -$0.32 vs consensus -$0.27 ▼ miss (-20.7%) filing →

Materiality & sentiment trend

Max materiality 0.80 · Median 0.70 · Most common event earnings

15 positive 2 negative 7 neutral

source · CLPT on sec.gov